Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 12/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | PYGL | P06737 | 1/20 | 0.40 |
| ▸ | PYGM | P11217 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14012237 | 0.92 | HRH4 (0.50) | HRH4HRH3HRH1KMT2ADRD3 | |
| SCHEMBL13311186 | 0.91 | HRH4 (0.51) | HRH4HRH3HRH1KMT2AMEN1 | |
| SCHEMBL13007046 | 0.90 | HRH4 (0.51) | HRH4HRH3HRH1KMT2AMEN1 | |
| SCHEMBL14546564 | 0.89 | HRH4 (0.44) | HRH4HRH3HRH1KMT2AMEN1 | |
| SCHEMBL10084804 | 0.88 | HRH4 (0.40) | HRH4HRH3HRH1SYK | |
| SCHEMBL13311170 | 0.85 | SYK (0.36) | HRH4HRH3HRH1SYK | |
| SCHEMBL12154889 | 0.85 | HRH4 (0.52) | HRH4HRH3HRH1KMT2AMEN1 | |
| SCHEMBL18584155 | 0.85 | HRH4 (0.39) | HRH4HRH3HRH1SYK | |
| SCHEMBL13805711 | 0.85 | HRH4 (0.40) | HRH4HRH3HRH1KMT2AMEN1 | |
| SCHEMBL14586775 | 0.85 | HRH4 (0.44) | HRH4KMT2APYGLPYGMDRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399403-B2 | drug-ligand conjugates that are potent cytotoxins; stabilized therapeutic agents and markers; exhibit high specificity of action, reduced toxicity, and improved stability in blood ; antitumors | MEDAREX, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20100092496-A1 | CHEMICAL LINKERS AND CONJUGATES THEREOF | MEDAREX, INC. (US) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100092496-A1 | CHEMICAL LINKERS AND CONJUGATES THEREOF | CLSPN, CD74, ANTXR2 | FPR2 805/4885HRH4 775/4885HRH3 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.